Full Press Release Details
SAN FRANCISCO, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (Nasdaq: KYNB), formerly FibroGen (Nasdaq: FGEN), today announced that the company’s management will participate in the following investor conferences:
Oppenheimer 36th Annual Healthcare Life Sciences ConferenceFormat: Corporate PresentationDate & Time: Thursday, February 26, 2026, 2:40-3:10 PM ETLocation: VirtualWebcast:https://event.summitcast.com/view/
Leerink Global Healthcare ConferenceFormat: Corporate PresentationDate & Time: Wednesday, March 11, 2026, 2:20-2:50 PM ETLocation: Miami, FLWebcast:https://event.summitcast.com/view/
Kyntra Bio’s management team will be available for one-on-one meetings during the conferences. Interested investors should contact their respective representatives to request a meeting. A replay of the presentations will be posted, when available, to theKyntra Biowebsite on theEvents & Presentationspage of the Investors and Media section for 90 days.
About Kyntra BioKyntra Bio is a biopharmaceutical company focused on development of novel therapies in oncology and rare disease. Roxadustat (爱瑞卓®, EVRENZO™) is currently approved in Europe, Japan, and numerous other countries for the treatment of anemia in chronic kidney disease (CKD) patients on dialysis and not on dialysis. The Company continues to evaluate the development plan for the Phase 3 trial of roxadustat in anemia associated with lower-risk myelodysplastic syndromes (LR-MDS) in the U.S. FG-3246 (also known as FOR46), a first-in-class antibody-drug conjugate (ADC) targeting CD46, is in Phase 2 development for the treatment of metastatic castration-resistant prostate cancer. This program also includes the development of FG-3180, an associated CD46-targeted PET biomarker. For more information, please visitwww.kyntrabio.com.